Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells

被引:17
作者
Ferry, KV
Fink, D
Johnson, SW
Nebel, S
Hamilton, TC
Howell, SB
机构
[1] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[2] Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA
关键词
DNA mismatch repair; cisplatin; drug resistance;
D O I
10.1016/S0006-2952(98)00366-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The proficiency of both nucleotide excision repair (NER) and DNA mismatch repair (MMR) influences cellular sensitivity to cisplatin (cis-diamminedichloroplatinum). To gain further insight into how MMR may influence platinum drug sensitivity, the effect of loss of MMR on repair synthesis was measured in vitro by a commonly used method that relies on whole-cell extracts to drive [alpha-P-32]dATP incorporation into cisplatin-damaged plasmid DNA. Extracts evaluated include those from cells with or without functional hMLH1 (HCT116+ch2 versus HCT116+ch3, respectively) and hMSH2 (HEC59 versus HEC59+ch2, respectively). Loss of MMR in the HCT116 system was associated with a 2.8-fold reduction in cisplatin damage-specific DNA synthesis, whereas it was associated with a 3.0-fold reduction in the HEC59 system, suggesting that a decrease in the ability to repair cisplatin damaged DNA accompanies loss of MMR. An in vitro DNA excision assay that utilized a substrate containing a site-specific cisplatin adduct was performed. Using this highly NER-specific assay, no significant difference was apparent between the extracts derived from NER-proficient versus-deficient cells. These and other data lead us to suggest that the increase in apparent repair synthesis in platinum-damaged plasmids by extracts from MMR-proficient versus-deficient cellular extracts may reflect a distinct and possibly adverse DNA synthetic process rather than productive NER. BIOCHEM PHARMACOL 57;8:861-867, 1999. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:861 / 867
页数:7
相关论文
共 26 条
[1]   MAMMALIAN DNA NUCLEOTIDE EXCISION-REPAIR RECONSTITUTED WITH PURIFIED PROTEIN-COMPONENTS [J].
ABOUSSEKHRA, A ;
BIGGERSTAFF, M ;
SHIVJI, MKK ;
VILPO, JA ;
MONCOLLIN, V ;
PODUST, VN ;
PROTIC, M ;
HUBSCHER, U ;
EGLY, JM ;
WOOD, RD .
CELL, 1995, 80 (06) :859-868
[2]  
Aebi S, 1996, CANCER RES, V56, P3087
[3]  
Anthoney DA, 1996, CANCER RES, V56, P1374
[4]  
BOYER JC, 1995, CANCER RES, V55, P6063
[5]   Human MutS alpha recognizes damaged DNA base pairs containing O-6-methylguanine, O-4-methylthymine, or the cisplatin-d(GpG) adduct [J].
Duckett, DR ;
Drummond, JT ;
Murchie, AIH ;
Reardon, JT ;
Sancar, A ;
Lilley, DM ;
Modrich, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (13) :6443-6447
[6]  
Fink D, 1996, CANCER RES, V56, P4881
[7]  
Fink D, 1997, INT J ONCOL, V11, P539
[8]  
Fink D, 1997, CANCER RES, V57, P1841
[9]   REPAIR AND TRANSCRIPTION - COLLISION OR COLLUSION [J].
HANAWALT, PC ;
DONAHUE, BA ;
SWEDER, KS .
CURRENT BIOLOGY, 1994, 4 (06) :518-521
[10]   DNA-DAMAGE TOLERANCE, MISMATCH REPAIR AND GENOME INSTABILITY [J].
KARRAN, P ;
BIGNAMI, M .
BIOESSAYS, 1994, 16 (11) :833-839